ArticleArthritis & rheumatology (Hoboken, N.J.)2016

Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.

Fenglong Xie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.